Titan Pharmaceuticals

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Titan Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 5 completed top decile by trial count

Titan Pharmaceuticals: 12 sponsored US clinical trials, none currently recruiting.

Titan Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 6 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Dependency, with 1 trials.

Top-decile sponsor footprint

Titan Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

5 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (41.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

TERMINATED Phase 1

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

NCT03250117
COMPLETED Phase 3

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
COMPLETED Phase 3

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

NCT01114308
TERMINATED Phase 3

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

NCT00768482
TERMINATED Phase 3

Study of Probuphine in Patients With Opioid Dependence

NCT00772785
COMPLETED Phase 3

Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00630201
COMPLETED Phase 3

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00447564
TERMINATED Phase 2

Study of DITPA in Patients With Congestive Heart Failure

NCT00103519
TERMINATED Phase 2

A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia

NCT00083473
TERMINATED Phase 1

A Pilot Study of Pivanex in Patients With Malignant Melanoma

NCT00087477
COMPLETED Phase 2

Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00073385
TERMINATED Phase 1

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

NCT00050687

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 6

Therapeutic Areas

Opioid Dependency 1

How the Titan Pharmaceuticals archive is shaped

12 indexed studies, none listed as recruiting (0% open); 5 completed (42%).

Phase mix: 6 late (III/IV) vs 6 early (I/II) (balanced across stages).

Top condition: Opioid Dependency (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Titan Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Titan Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Titan PharmaceuticalsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Titan Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Titan Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Titan Pharmaceuticals page

12 registered trials is a research-attention snapshot, not an endorsement of Titan Pharmaceuticals or any single study.

  • None of Titan Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Opioid Dependency is the condition Titan Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Dependency trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Titan Pharmaceuticals pipeline card: 12 registered trials from official public datasets.Report a data error.